Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients

References

• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Department of Health and Human Services, 2008
   Google Scholar
• Diabetes Atlas Committee. Diabetes Atlas Executive Summary: International Diabetes Federation, 2003
   Google Scholar
• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• Klonoff DC. News from the FDA. Diabetes Tech Therapeut 2000;2:289-92
   PubMedGoogle Scholar
• Juurlink DN. Rosiglitazone and the case for safety over certainty. JAMA 2010;304:469-71
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Tanne JH. FDA committees say keep rosiglitazone available but increase warnings. BMJ 2007;335:223
   PubMedGoogle Scholar
• Derosa G, Cicero AFG, D'angelo A, et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006;28:679-88
   PubMed Web of Science ®Google Scholar
• Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
   PubMed Web of Science ®Google Scholar
• Wolffenbuttel BHR, Gomist R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-7
   PubMed Web of Science ®Google Scholar
• Orbay E, Sargin M, Sargin H, et al. Addition of rosiglitazone to glimepiride and metformin combination therapy in type 2 diabetes. Endocr J 2004;6:521-7
   Google Scholar
• Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
   PubMed Web of Science ®Google Scholar
• Wijk JPHv, Koning EJPd, Martens EP, et al. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Throm Vasc Biol 2003;23:1744-9
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191-201
   PubMed Web of Science ®Google Scholar
• Lewin AJ, Kipnes MS, Meneghini LF, et al. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004;26:379-89
   PubMed Web of Science ®Google Scholar
• Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002;90:947-52
   PubMed Web of Science ®Google Scholar
• Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006;97:646-50
   PubMed Web of Science ®Google Scholar
• Tunis S, Minshall M, St Charles M, et al. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. Curr Med Res Opin 2008;24:3085-96
   PubMed Web of Science ®Google Scholar
• St Charles M, Minshall M, Pandya B, et al. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Curr Med Res Opin 2009;25:1343-53
   PubMed Web of Science ®Google Scholar
• Masoudi F. Improving drug safety surveillance: lessons from rosiglitazone. Circ Cardiovasc Qual Outcomes 2010;3:441-3
   PubMed Web of Science ®Google Scholar
• Woodcock J, Sharfstein J, Hamburg M. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. N Engl J Med 2010;363:1489-91
   PubMed Web of Science ®Google Scholar
• EMA. European Medicines Agency recommends suspension of Avandia Avandamet and Avaglim. Press release 23 September 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/09/WC500096996.pdf [last accessed January 10, 2011]
   Google Scholar
• Chisholm J. The Read Clinical Classification. BMJ 1990;300:1092
   PubMed Web of Science ®Google Scholar
• Perry J. OXMIS problem codes for primary medical care. Oxford, England: Oxmis Publications, 1978
   Google Scholar
• Yang Y-X, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-53
   PubMed Web of Science ®Google Scholar
• Rodriguez LAG, Gutthann SP. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25
   PubMed Web of Science ®Google Scholar
• Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997;350:1097-9
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DD. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-24
   Web of Science ®Google Scholar
• Rubin DB. Matching to remove bias in observations studies. Biometrics 1973;29:159-83
   Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform. J Health Econ 2001;20:461-94
   PubMed Web of Science ®Google Scholar
• Park R. Estimation with heteroscedastic error terms. Econometrica 1966;38:888
   Google Scholar
• SAS Institute Inc. SAS/STAT User's Guide, Version 9.1. Cary, NC, USA: SAS Institute, 2004
   Google Scholar
• Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378-95
   PubMed Web of Science ®Google Scholar
• Harmel AP, Kendall DM, Boyle PJ, et al. Impact of adjunctive thiazolindinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 2004;20:215-23
   PubMed Web of Science ®Google Scholar
• Phillips L, Grunberger G, Miller E, et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15
   PubMed Web of Science ®Google Scholar
• Lebovitz H, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
   PubMed Web of Science ®Google Scholar
• Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemia control in patients with type 2 diabetes mellitus. Diabet Med 2000;17:287-94
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes. Diabetes Care 2006;29:554-9
   PubMed Web of Science ®Google Scholar
• Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000
   PubMed Web of Science ®Google Scholar
• DiPiro JT, Talbert RL, Yee CC, et al. Pharmacotherapy: A Pathophysiologic Approach, 6th edn. New York, NY: McGraw-Hill, 2005
   Google Scholar
• Orrico K, Lin J, Wei A, et al. Clinical consequences of disseminating the rosiglitazone FDA safety warning. Am J Manag Care 2010;16:e111-e16
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Clinical Guideline G-Management of type 2 diabetes National Institute for Clinical Excellence September 2002
   Google Scholar
• Yu A, Wu EQ, Birnbaum H, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157-69
   PubMed Web of Science ®Google Scholar
• Martens F, Visseren F, Lemay J. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-80
   PubMed Web of Science ®Google Scholar
• Herman WH, Dirani RG, Horblyuk RO, et al. Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone: findings from the Rosiglitazone early vs SULfonylurea Titration (RESULT) study. Am J Manag Care 2005;11:273-8
   PubMed Web of Science ®Google Scholar
• Grahm DJ, Oullet-Hellstrom R, MaCurdy TE, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute. Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Baltimore, MD: National Institutes of Health, September 2002. Report No.: 02-5215
   Google Scholar